Oculis Holding AG

Oculis Holding AGverified

OCS

Price:

$19.7

Market Cap:

$829.02M

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Industry

Biotechnology

IPO Date

2021-05-18

Stock Exchange

NASDAQ

Ticker

OCS

The ROE as of December 2025 (TTM) for Oculis Holding AG (OCS) is -90.60%

According to Oculis Holding AG’s latest financial reports and current stock price. The company's current ROE is -90.60%. This represents a change of 268.26% compared to the average of -24.60% of the last 4 quarters.

Oculis Holding AG (OCS) Historical ROE (quarterly & annually)

How has OCS ROE performed in the past?

The mean historical ROE of Oculis Holding AG over the last ten years is -21.53%. The current -90.60% ROE has changed 320.85% with respect to the historical average. Over the past ten years (40 quarters), OCS's ROE was at its highest in in the June 2022 quarter at 15.60%. The ROE was at its lowest in in the December 2024 quarter at -39.05%.

Quarterly (TTM)
Annual

Average

-21.53%

Median

30.44%

Minimum

-116.89%

Maximum

39.49%

Oculis Holding AG (OCS) ROE by Quarter and Year

Discovering the peaks and valleys of Oculis Holding AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 29.75%

Maximum Annual ROE = 39.49%

Minimum Annual Increase = -339.91%

Minimum Annual ROE = -116.89%

Quarterly (TTM)
Annual
YearROEChange
2024-116.89%23.37%
2023-94.74%-339.91%
202239.49%29.75%
202130.44%-10.67%

Oculis Holding AG (OCS) Average ROE

How has OCS ROE performed in the past?

The current ROE of Oculis Holding AG (OCS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-57.38%

5-year avg

-21.53%

10-year avg

-21.53%

Oculis Holding AG (OCS) ROE vs. Peers

How is OCS’s ROE compared to its peers?

Oculis Holding AG’s ROE is greater than Xencor, Inc. (-26.73%), greater than Kodiak Sciences Inc. (-176.58%), greater than AnaptysBio, Inc. (-1101.24%), less than UroGen Pharma Ltd. (503.46%), less than Phathom Pharmaceuticals, Inc. (77.32%), greater than Nurix Therapeutics, Inc. (-53.57%), greater than Nektar Therapeutics (-356.81%), greater than Sana Biotechnology, Inc. (-115.33%), greater than BridgeBio Oncology Therapeutics Inc. (-77.14%), greater than Mind Medicine (MindMed) Inc. (-86.18%),

Build a custom stock screener for Oculis Holding AG (OCS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oculis Holding AG using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Oculis Holding AG (OCS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Oculis Holding AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Oculis Holding AG's ROE?

How is the ROE calculated for Oculis Holding AG (OCS)?

What is the highest ROE for Oculis Holding AG (OCS)?

What is the 3-year average ROE for Oculis Holding AG (OCS)?

What is the 5-year average ROE for Oculis Holding AG (OCS)?

How does the current ROE for Oculis Holding AG (OCS) compare to its historical average?